Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: According to the story, brand-name aromatase inhibitors cost between $340 and $420 a month, but the story also points out that lower-costing, generic versions are available in the U.S. It would have been useful had the story also provided cost information for the other preventive drug options, tamoxifen and raloxifene. A particular strength of this story is its presentation of data. Dr. Winer, an independent source included in the story, translates a 65% risk reduction to mean that exemestane may reduce a woman's risk of developing breast cancer from 3% to 1%. Not only does the story provide absolute risk, but it also presents the number needed to treat. According to the study authors, 26 women would need to take exemestane for five years to prevent a single case of breast cancer. It should be noted, however, that few women in the study completed five years of therapy. Since this is being used as a preventive measure in healthy women, side effects are very important and data should have been provided. The story indicates that "slightly" more women taking exemastane experienced hot flashes, fatigue, sweating, insomnia, and joint pain, compared to those taking placebo pills. It would have been helpful to note, for example, that 40% in the exemestane group experienced a hot flash versus 32% in the placebo group. Citing older research, the story indicates that that joint pain, muscle aches, problems having sex, and vaginal dryness may be more evident with a longer duration of use. The story makes it clear that the study was a large-scale, placebo-controlled, randomized trial, which enrolled over 4500 women in North America and Europe. The women included had at least one risk factor for breast cancer. It also notes that given the significant risk reduction associated with exemestane, the study was stopped after 3 years to give women in the control arm the option of taking exemestane to prevent possible breast cancers. More information regarding participants' characteristics, including age and race would have been helpful. This story did not engage in disease-mongering. In addition to including experts not affiliated with the exemestane study, the story also notes that the it was funded by the Canadian Cancer Society, the Avon Foundation, and Pfizer. In addition, the writer points out that the study lead and a few other authors have received speaking fees from Pfizer and other pharmaceutical companies that make cancer drugs. This story compares the benefits and harms of exemestane with tamoxifen; however, a mention of how these compare with raloxifene, would have been useful. The availability of aromatase inhibitors is not in question. It's clear from the story that aromatase inhibitors are currently used to prevent breast cancer recurrences. It's also clear that this is the first study evaluating its utility for preventing the first instance of breast cancer in healthy women with a higher risk of developing the disease. The story does not appear to be based on the press release.
Example Output: Hormone-blocking drug reduces breast cancer risk

Example Input: Bayer acquired Monsanto this year for $63 billion. "If we can settle nuisances at some point where the defense costs in preparing cases are higher than potential settlement amounts, we will of course consider it from an economic standpoint," CEO Werner Baumann told reporters when asked whether there was any scenario in which Bayer would consider settling. He added: "We will resolutely and with all means defend ourselves in this (glyphosate) litigation." Baumann was speaking on Monday to German media invited to visit Bayer's new operations in the former research and development facilities of Monsanto in St. Louis, Missouri. The remarks, made on Monday, were embargoed to the end of the week to allow media to return home. Shares in Bayer have lost 25 percent in value since Aug. 10, when a San Francisco jury awarded $289 million to Dewayne Johnson on grounds Monsanto failed to warn the school groundskeeper and other consumers of the cancer risks posed by glyphosate-based RoundUp and Ranger Pro. Johnson has terminal non-Hodgkin's lymphoma that he alleges was caused by the herbicides. A judge later reduced the award to $78 million. Bayer denies that glyphosate causes cancer and says decades of scientific studies and real-world use have shown the chemical to be safe for human use. The company is appealing the findings. The number of glyphosate cases that Bayer faces across the United States has jumped to more than 8,700, prompting concerns among investors about the impact of litigation costs on Bayer's bottom line. Baumann expressed confidence that Bayer could handle the litigation, and cited its "inexpensive" $12 million settlement of 4,000 lawsuits over its contraceptive Mirena device. Bayer also won five of six trials over its best-selling bloodthinner Xarelto, over which it faces 24,000 U.S. lawsuits. The sixth jury found in favor of a plaintiff, but a judge later overturned the decision. "Due to our exposure as a pharmaceutical company, we have the experience to defend those (glyphosate) cases," he said. Baumann said the company's legal strategy had been revised following the integration of Bayer and Monsanto in mid-August. He declined to provide details, but recent court filings reveal some of the steps the company has taken. Last week, Bayer added the attorneys from law firm Arnold & Portner who won the Xarelto cases for the company to its glyphosate defense team. It is also trying to change the juror selection process for upcoming trials. In filings last week in San Francisco federal court, where a new glyphosate trial is scheduled to begin on Feb. 25, 2019, Bayer said the "jury pool likely has grown more hostile" due to negative media coverage following the Johnson verdict. Michael Miller, one of the attorneys for the plaintiff, said the company's claims were "hypocritical beyond belief" given its own efforts to control the message on glyphosate, most recently in a full-page advertisement in the Washington Post. Bayer has asked U.S. District Judge Vince Chhabria, who is overseeing the San Francisco case and some 580 others, to significantly expand the jury pool and question prospective jurors about their knowledge of the media coverage of the cases. Chhabria is expected to decide on the requests in December.
Example Output: Bayer CEO says would consider glyphosate settlement depending on costs.

Example Input: "To prevent the spread of coronavirus, one state lawmaker wants to take the ""assembly"" out of the North Carolina General Assembly. North Carolina state Rep. Kelly Alexander, a Democrat from Mecklenburg County, suggested on Twitter that legislators should consider video conferencing. The start of the legislature's session is scheduled for April 28. Alexander posted his tweet on March 11. That same day the World Health Organization labeled the spread of the novel coronavirus as a ""pandemic,"" prompting a wave of event cancellations and changes across the globe. ""With a vaccine a year in the future the General Assembly should use more teleconferences and fewer in person meetings to cut down on potential exposure...after all most of the GA's members are in the high risk age group,"" Alexander tweeted, adding: ""besides we need to modernize...just saying."" Is it that ""most"" of North Carolina's legislators are in the ""high risk age group?"" Alexander never responded to an email from PolitiFact, so we don't know how he came to his conclusion. Regardless, his tweet is on-point. First, let's first look at what health experts say about the novel coronavirus (also known as COVID-19) and who's most at-risk. The virus causes a fever, cough and shortness of breath in people anywhere from two to 14 days after exposure, according to the the Centers for Disease Control and Prevention. The CDC says people with chronic medical conditions such as heart disease, diabetes or lung disease are most at-risk. As for age, there's no specific birth date at which people become more vulnerable. Generally speaking: the older you are, the more likely you are to have complications from the novel coronavirus. That said, top health organizations have defined ""older adults"" as people who are at least 60 years old. The CDC has previously, in a document unrelated to the coronavirus, defined older adults as those over 60. The World Health Organization specifically mentioned people over 60 in its recent report on the coronavirus outbreak in China. Health experts recently told CNN that the term ""older"" typically refers to anyone over 60. And US Surgeon General Jerome Adams said 60 is the ""average age of people who need medical attention."" It also appears that people older than 60 are more susceptible to complications from the virus. Scientific American reported that patients in China were more at-risk of death if they developed acute respiratory distress syndrome, known as ARDS, after contracting coronavirus. The average age of those who contracted the syndrome was 61. So we know that people who are 60-years-old or older are likely to be more at-risk than other age groups. With this in mind, let's look at the age of North Carolina's legislators. The legislature includes 170 members: 120 in the House and 50 in the Senate. In the Senate, 28 members are 60-years-old or older. In the House, 63 members are older than 60. That means 91 members are aged 60 or older -- which is 53% of the General Assembly. Those numbers come from James White, the House principal clerk, and Sarah Holland, the Senate's principal clerk. So it's that a majority of legislators are 60 or older. How does that compare to Congress? In the U.S. House, 197 of its 435 members are 60 or older. In the U.S. Senate, 66 of its 100 members are 60 or older. That means about 49% of Congress is at least 60 years-old. Those numbers come from a report by the Congressional Research Service and Jennifer Manning, the service's senior research librarian. Rep. Alexander said ""most"" North Carolina legislators are in the ""highest risk age group"" for coronavirus. The highest risk age group is generally people who are aged 60 and older. Alexander's claim is on-point: more than half of legislators are older than that."
Example Output:
Kelly Alexander Says "most" NC legislators are in the "high risk age group" for coronavirus